1
|
Bräutigam J, Bischoff I, Schürmann C, Buchmann G, Epah J, Fuchs S, Heiss E, Brandes RP, Fürst R. Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2. J Mol Cell Cardiol 2019; 135:97-108. [PMID: 31381906 DOI: 10.1016/j.yjmcc.2019.08.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Revised: 07/22/2019] [Accepted: 08/01/2019] [Indexed: 11/18/2022]
Abstract
The process of angiogenesis is involved in several pathological conditions, such as tumor growth or age-related macular degeneration. Although the available anti-angiogenic drugs have improved the therapy of these diseases, major drawbacks, such as unwanted side effects and resistances, still exist. Consequently, the search for new anti-angiogenic substances is still ongoing. Narciclasine, a plant alkaloid from different members of the Amaryllidaceae family, has extensively been characterized as anti-tumor compound. Beyond the field of cancer, the compound has recently been shown to possess anti-inflammatory properties. Surprisingly, potential actions of narciclasine on endothelial cells in the context of angiogenesis have been neglected so far. Thus, we aimed to analyze the effects of narciclasine on angiogenic processes in vitro and in vivo and to elucidate the underlying mechanism. Narciclasine (100-300 nM) effectively inhibited the proliferation, undirected and directed migration, network formation and angiogenic sprouting of human primary endothelial cells. Moreover, narciclasine (1 mg/kg/day) strongly reduced the VEGF-triggered angiogenesis in vivo (Matrigel plug assay in mice). Narciclasine mediated its anti-angiogenic effects in part by a RhoA-independent activation of the Rho kinase ROCK. Most importantly, however, the compound reduced the de novo protein synthesis in endothelial cells by approx. 50% without exhibiting considerable cytotoxic effects. As a consequence, narciclasine diminished the presence of proteins with a short half-life, such as the VEGF receptor 2, which is the basis for its anti-angiogenic effects. Taken together, our study highlights narciclasine as an interesting anti-angiogenic compound that is worth to be further evaluated in preclinical studies.
Collapse
Affiliation(s)
- Jacqueline Bräutigam
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University, Frankfurt, Germany
| | - Iris Bischoff
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University, Frankfurt, Germany
| | - Christoph Schürmann
- Institute for Cardiovascular Physiology, Faculty of Medicine, Goethe University, Frankfurt, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Frankfurt, Germany
| | - Giulia Buchmann
- Institute for Cardiovascular Physiology, Faculty of Medicine, Goethe University, Frankfurt, Germany
| | - Jeremy Epah
- Institute for Cardiovascular Physiology, Faculty of Medicine, Goethe University, Frankfurt, Germany
| | - Simone Fuchs
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University, Frankfurt, Germany
| | - Elke Heiss
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - Ralf P Brandes
- Institute for Cardiovascular Physiology, Faculty of Medicine, Goethe University, Frankfurt, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Frankfurt, Germany
| | - Robert Fürst
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University, Frankfurt, Germany.
| |
Collapse
|
2
|
Stark A, Schwenk R, Wack G, Zuchtriegel G, Hatemler MG, Bräutigam J, Schmidtko A, Reichel CA, Bischoff I, Fürst R. Narciclasine exerts anti-inflammatory actions by blocking leukocyte-endothelial cell interactions and down-regulation of the endothelial TNF receptor 1. FASEB J 2019; 33:8771-8781. [PMID: 31017817 DOI: 10.1096/fj.201802440r] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The alkaloid narciclasine has been characterized extensively as an anticancer compound. Accumulating evidence suggests that narciclasine has anti-inflammatory potential; however, the underlying mechanism remains poorly understood. We hypothesized that narciclasine affects the activation of endothelial cells (ECs), a hallmark of inflammatory processes, which is a prerequisite for leukocyte-EC interaction. Thus, we aimed to investigate narciclasine's action on this process in vivo and to analyze the underlying mechanisms in vitro. In a murine peritonitis model, narciclasine reduced leukocyte infiltration, proinflammatory cytokine expression, and inflammation-associated abdominal pain. Moreover, narciclasine decreased rolling and blocked adhesion and transmigration of leukocytes in vivo. In cultured ECs, narciclasine inhibited the expression of cell adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin and blocked crucial steps of the NF-κB activation cascade: NF-κB promotor activity, p65 nuclear translocation, inhibitor of κB α (IκBα) phosphorylation and degradation, and IκBα kinase β and TGF-β-activated kinase 1 phosphorylation. Interestingly, these effects were based on the narciclasine-triggered loss of TNF receptor 1 (TNFR1). Our study highlights narciclasine as an interesting anti-inflammatory compound that effectively inhibits the interaction of leukocytes with ECs by blocking endothelial activation processes. Most importantly, we showed that the observed inhibitory action of narciclasine on TNF-triggered signaling pathways is based on the loss of TNFR1.-Stark, A., Schwenk, R., Wack, G., Zuchtriegel, G., Hatemler, M. G., Bräutigam, J., Schmidtko, A., Reichel, C. A., Bischoff, I., Fürst, R. Narciclasine exerts anti-inflammatory actions by blocking leukocyte-endothelial cell interactions and down-regulation of the endothelial TNF receptor 1.
Collapse
Affiliation(s)
- Anna Stark
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry, and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| | - Rebecca Schwenk
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry, and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| | - Gesine Wack
- Institute of Pharmacology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| | - Gabriele Zuchtriegel
- Department of Otorhinolaryngology, Head and Neck Surgery-Walter Brendel Center of Experimental Medicine, University of Munich, Munich, Germany
| | - Melissa G Hatemler
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry, and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| | - Jacqueline Bräutigam
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry, and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| | - Achim Schmidtko
- Institute of Pharmacology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| | - Christoph A Reichel
- Department of Otorhinolaryngology, Head and Neck Surgery-Walter Brendel Center of Experimental Medicine, University of Munich, Munich, Germany
| | - Iris Bischoff
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry, and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| | - Robert Fürst
- Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry, and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany
| |
Collapse
|
3
|
Bräutigam J, Nguyen Dieu L, Heiss E, Bischoff I, Fürst R. Inhibition of angiogenic key features: the Amaryllidaceae alkaloid narciclasine diminishes proliferation, migration, tube formation and sprouting of human endothelial cells. Am J Transl Res 2017. [DOI: 10.1055/s-0037-1608107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- J Bräutigam
- Institute of Pharmaceutical Biology, Biocenter, Goethe University, Frankfurt/Main, Germany
| | - L Nguyen Dieu
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - E Heiss
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - I Bischoff
- Institute of Pharmaceutical Biology, Biocenter, Goethe University, Frankfurt/Main, Germany
| | - R Fürst
- Institute of Pharmaceutical Biology, Biocenter, Goethe University, Frankfurt/Main, Germany
| |
Collapse
|
4
|
Fuchs S, Bischoff I, Willer EA, Bräutigam J, Bubik MF, Erdelmeier CAJ, Koch E, Faleschini MT, De Mieri M, Bauhart M, Zahler S, Hensel A, Hamburger M, Potterat O, Fürst R. The Dual Edema-Preventing Molecular Mechanism of the Crataegus Extract WS 1442 Can Be Assigned to Distinct Phytochemical Fractions. Planta Med 2017; 83:701-709. [PMID: 28006832 DOI: 10.1055/s-0042-123388] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The hawthorn (Crataegus spp.) extract WS 1442 is used against mild forms of chronic heart failure. This disease is associated with endothelial barrier dysfunction and edema formation. We have recently shown that WS 1442 protects against this dysfunction by a dual mechanism: it both promotes endothelial barrier integrity by activation of a barrier-enhancing pathway (cortactin activation) and inhibits endothelial hyperpermeability by blocking a barrier disruptive pathway (calcium signaling). In this study, we aimed to identify the bioactive compounds responsible for these actions by using a bioactivity-guided fractionation approach. From the four fractions generated from WS 1442 by successive elution with water, 95 % ethanol, methanol, and 70 % acetone, only the water fraction was inactive, whereas the other three triggered a reduction of endothelial hyperpermeability. Analyses of intracellular calcium levels and cortactin phosphorylation were used as readouts to estimate the bioactivity of subfractions and isolated compounds. Interestingly, only the ethanolic fraction interfered with the calcium signaling, whereas only the methanolic fraction led to an activation of cortactin. Thus, the dual mode of action of WS 1442 could be clearly assigned to two distinct fractions. Although the identification of the calcium-active substance(s) was not successful, we could exclude an involvement of phenolic compounds. Cortactin activation, however, could be clearly attributed to oligomeric procyanidins with a distinct degree of polymerization. Taken together, our study provides the first approach to identify the active constituents of WS 1442 that address different cellular pathways leading to the inhibition of endothelial barrier dysfunction.
Collapse
Affiliation(s)
- Simone Fuchs
- Institute of Pharmaceutical Biology, Goethe University Frankfurt/Main
| | - Iris Bischoff
- Institute of Pharmaceutical Biology, Goethe University Frankfurt/Main
| | - Elisabeth A Willer
- Pharmaceutical Biology, Department of Pharmacy, Center for Drug Research, University of Munich
| | | | - Martin F Bubik
- Pharmaceutical Biology, Department of Pharmacy, Center for Drug Research, University of Munich
| | | | - Egon Koch
- Preclinical Research, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe
| | - Maria T Faleschini
- Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland
| | - Maria De Mieri
- Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland
| | - Milena Bauhart
- Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland
| | - Stefan Zahler
- Pharmaceutical Biology, Department of Pharmacy, Center for Drug Research, University of Munich
| | - Andreas Hensel
- Institute of Pharmaceutical Biology and Phytochemistry, University of Münster
| | - Matthias Hamburger
- Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland
| | - Olivier Potterat
- Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland
| | - Robert Fürst
- Institute of Pharmaceutical Biology, Goethe University Frankfurt/Main
| |
Collapse
|
5
|
Mattsson H, Havu N, Bräutigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 1991; 100:311-9. [PMID: 1985029 DOI: 10.1016/0016-5085(91)90197-s] [Citation(s) in RCA: 90] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Studies in the rat have shown that partial gastric corpectomy, in which about 75% of the acid-producing oxyntic mucosa was removed, leads to markedly reduced acid secretion and a feedback increase in the plasma gastrin levels. Ten weeks after operation, the gastric enterochromaffin (ECL)-like cell density in the remaining part of the oxyntic mucosa had increased significantly. In the present study, the effects on the gastric ECL cells of lifelong persistent hypergastrinemia induced by partial (75%) corpectomy have been investigated. Seventy-five partially corpectomized rats and 40 control rats were investigated for plasma gastrin and oxyntic mucosal changes in a 124-week study. The partially corpectomized rats showed increased plasma gastrin levels after the operation; the mean increase compared with the controls was almost 10-fold during the entire study. The remaining oxyntic mucosa of the partially corpectomized rats differed from that of control rats in two respects, showing first general hypertrophy and second a marked hyperplasia of argyrophil ECL cells. The degree and incidence of these changes increased towards the end of the study, i.e., in the aging rats. An age-related increase in ECL-cell density occurred spontaneously also in the control rats but to a lesser extent than in the partially corpectomized group. ECL-cell carcinoids were found in the oxyntic mucosa of 26 of the 75 partially corpectomized rats. The first carcinoid was found 78 weeks after the beginning of the study. Six rats with carcinoids (23%) were found before week 104 (2 years) and the remainder, 20 (77%), were discovered later. No carcinoid tumor was found in the control rats. It is concluded that lifelong hypergastrinemia induced by partial corpectomy leads to the development of ECL-cell carcinoids in the oxyntic mucosa of some rats towards the end of their life span. This observation strongly supports the hypothesis that the gastric ECL-cell carcinoids found in rats treated with antisecretory drugs are caused by long-standing hypergastrinemia developing secondary to inhibition of gastric acid secretion.
Collapse
Affiliation(s)
- H Mattsson
- Gastrointestinal Research, AB Hässle, Mölndal, Sweden
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
The eyes from pigmented rabbits were instilled with the beta-adrenoceptor antagonists H 216/44 or timolol. After a single instillation (1.9 mumol), the iris and ciliary body contained H 216/44, which decreased with a half-life of approx. 43 days. Daily instillation caused a gradual increase in the content of H 216/44 and timolol in the iris and ciliary body, the steady-state concentration of timolol being 10 times higher than that of H 216/44. The concentrations of H 216/44 were seven times higher in the iris and ciliary body of pigmented rabbits than in albino animals. H 216/44 was reversibly bound to the melanosomes from the iris and ciliary body and not metabolized in this tissue. In vitro binding of timolol and H 216/44 to bovine melanosomes showed comparable multi-site binding curves. The binding of chlorpromazine was substantially higher. The beta-blockers could be more readily released from the melanosomes with aqueous solutions of salt and ethanol than with distilled water. It is concluded that both H 216/44 and timolol bind reversibly to ocular melanin. The differences in binding characteristics in vitro may only partly explain the differences in the in vivo binding to ocular melanin in the rabbit eye.
Collapse
|
7
|
Lindqvist P, Olsson G, Nordborg C, Bondjers G, Bräutigam J, Ostlund-Lindqvist AM. Atherosclerosis in rabbits identified as high and low responders to an atherogenic diet and the effect of treatment with a beta 1-blocker. Atherosclerosis 1988; 72:163-72. [PMID: 3214467 DOI: 10.1016/0021-9150(88)90077-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
In order to investigate whether initial plasma lipid concentrations could be used to distinguish between high and low responders to an atherogenic diet, rabbits were divided into 3 groups according to their plasma concentrations of cholesterol and phospholipids after 4 weeks on a standard rabbit diet. Plasma cholesterol and phospholipid levels were less than 0.5 mM, less than 1.1 mM, respectively, in group 1 (n = 17), greater than 0.5 mM, less than 1.1 mM, in group 2 (n = 13), and greater than 0.5 mM, greater than or equal to 1.1 mM, in group 3 (n = 14). After 7 weeks on a diet containing 0.25% cholesterol and 3% coconut oil, animals in groups 1 and 2 had a lower increase in their plasma lipid levels compared with group 3. Half of each group was then treated with the beta 1-adrenoceptor antagonist metoprolol during the next 14 weeks on the atherogenic diet. At the end of the study, the extent of atherosclerosis both in the aortas and in the coronary arteries of the control animals showed a positive correlation to plasma cholesterol and to plasma phospholipid concentrations integrated over time. The metoprolol-treated animals in groups 1 and 2 had a reduction of atherosclerosis compared with their respective controls. We conclude that subpopulations of rabbits that react differently on an atherogenic diet can be identified by their initial plasma lipid levels, and that metoprolol treatment of low responders to an atherogenic diet significantly reduces atherosclerotic lesions of the aorta.
Collapse
Affiliation(s)
- P Lindqvist
- Department of Medical and Physiological Chemistry, University of Uppsala, Sweden
| | | | | | | | | | | |
Collapse
|
8
|
Ostlund-Lindqvist AM, Lindqvist P, Bräutigam J, Olsson G, Bondjers G, Nordborg C. Effect of metoprolol on diet-induced atherosclerosis in rabbits. Arteriosclerosis 1988; 8:40-5. [PMID: 3341991 DOI: 10.1161/01.atv.8.1.40] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The effect of metoprolol, a beta 1-blocker, on atherogenesis was evaluated in rabbits fed a diet supplemented with 0.25% cholesterol and 3% coconut oil for 21 weeks. After 7 weeks on the diet, the rabbits were randomly divided into treated (n = 22) and untreated (n = 22) groups. Treated animals received metoprolol subcutaneously by an osmotic pump for 14 weeks, resulting in a plasma level of 774 +/- 69 nM during the investigation. Plasma concentrations of cholesterol, triglycerides, and phospholipids did not differ between the two groups. Nor were there any significant differences between the two groups in plasma concentrations of apolipoprotein A-I, apolipoprotein B, apolipoprotein C-III, and apolipoprotein E measured by electroimmunoassay. At the end of the study, the aortas were cut into three portions and the extent of atherosclerosis was determined by morphometry. The group that had received metoprolol had significantly (p less than 0.015) less atherosclerosis in the aorta (ascending plus arch 37.8 +/- 6.8%, thoracic 32.9 +/- 6.1%, abdominal 19.8 +/- 6.1% of total intimal area; mean +/- SEM) than the controls (ascending plus arch 54.9 +/- 7.1%, thoracic 48.0 +/- 6.2%, abdominal 25.9 +/- 5.5%).
Collapse
Affiliation(s)
- A M Ostlund-Lindqvist
- Department of Pharmacology and Biochemistry, Hässle Research Laboratories, Mölndal, Sweden
| | | | | | | | | | | |
Collapse
|
9
|
Wilderer P, Bräutigam J, Sekoulov I. Application of gas permeable membranes for auxiliary oxygenation of sequencing batch reactors. ACTA ACUST UNITED AC 1985. [DOI: 10.1016/0361-3658(85)90035-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|